

Yangonin

Catalog No: tcsc4243



Available Sizes

Size: 5mg

Size: 10mg



Specifications

CAS No:

500-62-9

Formula:

$C_{15}H_{14}O_4$

Pathway:

GPCR/G Protein;NF-κB

Target:

Cannabinoid Receptor;NF-κB

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

258.27

Product Description


Yangonin exhibits affinity for the human recombinant cannabinoid **CB1 receptor** with an **IC₅₀** and a **K_i** of $1.79 \pm 0.53 \mu\text{M}$ and $0.72 \pm 0.21 \mu\text{M}$, respectively.

IC50 & Target: IC50: $1.79 \pm 0.53 \mu\text{M}$ (hCB1 receptor), $>10 \mu\text{M}$ (hCB2 receptor)^[1]

Ki: 0.72 ± 0.21 μ M (hCB1 receptor), >10 μ M (hCB2 receptor)^[1]

RelA/p65^[2]

In Vitro: Yangonin is one of the six major kavalactones found in *Piper methysticum*. Yangonin potently inhibits NF- κ B activation through suppression of the transcriptional activity of the RelA/p65 subunit of NF- κ B. Yangonin significantly inhibits the induced expression of the NF- κ B-reporter gene. However, Yangonin does not interfere with TNF- α -induced inhibitor of κ B α (I κ B α) degradation, p65 nuclear translocation, and DNA-binding activity of NF- κ B. Yangonin inhibits not only the induced NF- κ B activation by overexpression of RelA/p65, but also transactivation activity of RelA/p65. Yangonin does not inhibit TNF- α -induced activation of p38, but it significantly impairs activation of ERK 1/2 and stress-activated protein kinase/JNK^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!